1 WEEK INVESTOR DEADLINE: Insulet Corporation Investors with Substantial Losses Have Opportunity to Lead the Insulet Class Action Lawsuit Before August 31, 2026 Deadline - PODD

Purchasers or acquirers of Insulet Corporation (NASDAQ: PODD) securities between February 21, 2025 and May 26, 2026, both dates inclusive, have until August 31, 2026 to seek appointment as lead plaintiff of the Insulet class action lawsuit. The Insulet class action lawsuit charges Insulet and certain of Insulet's top current and former executive officers with violations of the Securities Exchange Act of 1934.

Insulet develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The Insulet class action lawsuit alleges that defendants throughout the Class Period made false and/or misleading statements and/or failed to disclose that: (i) Insulet's manufacturing controls and procedures were defective; (ii) the foregoing created a foreseeable heightened risk that one or more Insulet products would be found to be in violation of applicable safety regulations and/or pose a risk of injury; and (iii) the manufacturing issue that precipitated Insulet's March 2026 Medical Device Correction affected a greater number of Insulet Pod products than Insulet claimed.

On March 12, 2026, Insulet allegedly disclosed that it had "initiated a voluntary Medical Device Correction for specific lots of Omnipod® 5 Pods after identifying a manufacturing issue through its ongoing product monitoring." On this news, the price of Insulet stock fell nearly 7%, according to the complaint.

Then, on May 26, 2026, Insulet allegedly disclosed the initation of another "voluntary Medical Device Correction," this time "for specific lots of Omnipod® 5, Omnipod Dash®, and Omnipod® Insulin Management System (Omnipod Eros) Pods due to a manufacturing issue, identified through ongoing product monitoring, that could result in insulin under-delivery." On this news, the price of Insulet stock fell more than 5%, according to the complaint.

The Private Securities Litigation Reform Act of 1995 permits any investor who purchased or acquired Insulet securities during the Class Period to seek appointment as lead plaintiff in the Insulet class action lawsuit.